Monkeypox
MONDO:0002594An infection that is caused by an Orthopoxvirus, which is transmitted by primates or rodents, and which is characterized by a prodromal syndrome of fever, chills, headache, myalgia, and lymphedema; initial symptoms are followed by a generalized papular rash that typically progresses from vesiculation through crusting over the course of two weeks.
Also known as: Monkeypox virus infection, infections, Monkeypox virus
66 clinical trials for this condition and its sub-types.
Follow this condition — get notified about new trialsBroader categories
-
Mpox vaccine trial for infants: could a Half-Dose protect just as well?
⭐️ VACCINE ⭐️ OngoingThis Phase 3 study is testing the MVA-BN mpox vaccine in 344 infants and children aged 4 to 24 months in the Democratic Republic of the Congo, a region heavily affected by mpox. Researchers are comparing a standard dose to a half-dose to see if the lower dose is still effective a…
Phase: PHASE3 • Sponsor: Jean-Pierre Van geertruyden • Aim: ⭐️ VACCINE ⭐️
Last updated Jun 27, 2026 12:25 UTC
-
Mpox vaccine gets a production upgrade: new cell recipe under trial
⭐️ VACCINE ⭐️ OngoingThis study tests whether the MVA-BN mpox vaccine (Jynneos) works as well when made in quail cells instead of chicken cells. About 970 healthy adults aged 18 to 49 will receive two doses four weeks apart. Researchers will compare immune responses and side effects between the two v…
Phase: PHASE2 • Sponsor: Bavarian Nordic • Aim: ⭐️ VACCINE ⭐️
Last updated Jun 27, 2026 12:05 UTC
-
Mpox vaccine trial for pregnant women launches in congo
⭐️ VACCINE ⭐️ OngoingThis Phase 3 trial is testing the safety and immune response of the MVA-BN mpox vaccine in 359 pregnant and postpartum women in the Democratic Republic of the Congo. Some women receive the vaccine during pregnancy, others right after giving birth, and a small group gets it as an …
Phase: PHASE3 • Sponsor: Jean-Pierre Van geertruyden • Aim: ⭐️ VACCINE ⭐️
Last updated Jun 27, 2026 09:00 UTC
-
Mpox vaccine trial expands to children: a step toward broader protection
⭐️ VACCINE ⭐️ OngoingThis study tests the MVA-BN vaccine in 460 children aged 2 to 12 years, comparing their immune response and safety to adults. All participants receive two doses four weeks apart. The goal is to see if the vaccine can prevent smallpox, mpox, and related orthopoxvirus infections in…
Phase: PHASE2 • Sponsor: Bavarian Nordic • Aim: ⭐️ VACCINE ⭐️
Last updated Jun 27, 2026 07:59 UTC
-
Can a pill speed up monkeypox recovery? major trial underway
Disease control OngoingThis study tests whether the antiviral drug tecovirimat can help people with monkeypox heal faster. About 480 adults and teens (14+) with active lesions will receive either tecovirimat or a placebo, alongside standard care. The main goal is to see how quickly skin and mouth sores…
Phase: PHASE3 • Sponsor: ANRS, Emerging Infectious Diseases • Aim: Disease control
Last updated Jun 27, 2026 12:37 UTC
-
Hospital at home: new study tests home care for infections
Disease control OngoingThis study looks at whether a special team of doctors and nurses can treat adults with suspected infections at home, instead of sending them to the hospital. About 500 people will be randomly assigned to either standard hospital care or home-based care from a mobile response team…
Phase: NA • Sponsor: Copenhagen University Hospital at Herlev • Aim: Disease control
Last updated Jun 27, 2026 11:00 UTC
-
Canadian trial tests monkeypox drug in outpatients
Disease control TerminatedThis Canadian study tests whether the antiviral drug tecovirimat (TPOXX) helps non-hospitalized adults with monkeypox recover faster. About 120 participants will receive either the drug or a placebo. The main goal is to see how quickly skin lesions heal and whether running such a…
Phase: PHASE3 • Sponsor: Marina Klein • Aim: Disease control
Last updated Jun 27, 2026 09:10 UTC
-
Mpox vaccine trial targets HIV-Positive adults in DRC
Prevention OngoingThis study is testing whether the MVA-BN mpox vaccine is safe and triggers a strong immune response in 600 adults living with HIV in Kinshasa, DRC. Participants receive two vaccine doses 28 days apart and are grouped by their CD4 count. The goal is to see if the vaccine works wel…
Phase: PHASE2 • Sponsor: Institute of Tropical Medicine, Belgium • Aim: Prevention
Last updated Jun 27, 2026 12:35 UTC
-
Could a Decades-Old smallpox vaccine stop mpox? colombia trial aims to find out
Prevention OngoingThis Phase 3 trial in Colombia tests the LC16m8 vaccine, originally developed for smallpox, to see if it can prevent mpox in people at high risk, such as men who have sex with men and those with HIV. About 8,686 participants will be randomly assigned to get the vaccine right away…
Phase: PHASE3 • Sponsor: Universidad Nacional de Colombia • Aim: Prevention
Last updated Jun 26, 2026 14:03 UTC
-
AI toolkit aims to speed up epidemic response for diseases like COVID-19 and mpox
Knowledge-focused ENROLLING_BY_INVITATIONThis study tests a new AI-powered toolkit designed to help public health officials at local CDC offices respond more quickly to emerging infectious diseases such as COVID-19, mpox, influenza, and dengue. The toolkit combines data analysis, risk assessment, decision support, and e…
Phase: NA • Sponsor: Peking University • Aim: Knowledge-focused
Last updated Jul 03, 2026 00:00 UTC
-
Scientists compare immune responses to viral and bacterial infections in ICU patients
Knowledge-focused OngoingThis study looks at how the immune system of patients in the intensive care unit (ICU) responds to severe infections caused by viruses or bacteria. Researchers will take extra blood samples from 38 adults to analyze immature granulocytes, a type of immune cell. The goal is to see…
Phase: NA • Sponsor: University Hospital, Limoges • Aim: Knowledge-focused
Last updated Jun 28, 2026 00:00 UTC
-
Mpox vaccine immune response under the microscope in DRC
Knowledge-focused OngoingThis study follows 300 adults in the Democratic Republic of the Congo who received either the MVA-BN or LC16m8 mpox vaccine as part of a national campaign. Researchers collect blood samples at several time points to measure how well the vaccines trigger and maintain antibodies ag…
Phase: PHASE4 • Sponsor: Institute of Tropical Medicine, Belgium • Aim: Knowledge-focused
Last updated Jun 27, 2026 13:07 UTC
-
AI predicts hospital stays, but study never started
Knowledge-focused TerminatedThis study aimed to see if a computer could learn to predict how long a patient would stay in a home hospital program. Researchers planned to use data from past patients to train the computer. However, the study was withdrawn before any patients were enrolled, so no results are a…
Sponsor: Brigham and Women's Hospital • Aim: Knowledge-focused
Last updated Jun 27, 2026 11:03 UTC
-
New study to reveal how well mpox vaccine works in HIV patients
Knowledge-focused ENROLLING_BY_INVITATIONThis study looks at how well the mpox vaccine works and how safe it is in people with HIV compared to those without HIV. About 174 adults who either recently got the mpox vaccine or had a recent mpox infection will take part. The goal is to fill important knowledge gaps and help …
Sponsor: NYU Langone Health • Aim: Knowledge-focused
Last updated Jun 27, 2026 07:56 UTC
-
Immune cell showdown: autoimmune vs. infection vs. healthy
Knowledge-focused ENROLLING_BY_INVITATIONThis study looks at immune cells from people with autoimmune diseases (like lupus), people with infections, and healthy volunteers. Researchers want to understand how these cells differ and what makes them attack the body in autoimmune conditions. The study involves blood and bon…
Sponsor: Emory University • Aim: Knowledge-focused
Last updated Jun 27, 2026 07:53 UTC